Efficient cancer immunogenetherapy by tumor cell lysate modified mRNA formulation
- 2 June 2025
- journal article
- Published by Elsevier in Biomaterials
- Vol. 324, 123466
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Department of Sichuan Province (23NSFJQ0104)
- Fundo para o Desenvolvimento das Ciências e da Tecnologia (0044/2024/ITP2,0001/2024/RDP)
- National Natural Science Foundation of China (U24A20735)
- National Natural Science Foundation of China (82473289)
This publication has 60 references indexed in Scilit:
- Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironmentBiomaterials, 2022
- Bifunctional Fusion Membrane‐Based Hydrogel Enhances Antitumor Potency of Autologous Cancer Vaccines by Activating Dendritic CellsAdvanced Functional Materials, 2022
- Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in miceBiomaterials, 2021
- The challenge and prospect of mRNA therapeutics landscapeBiotechnology Advances, 2020
- PEGylated tumor cell membrane vesicles as a new vaccine platform for cancer immunotherapyBiomaterials, 2018
- Strategies to overcome the polycation dilemma in drug deliveryAdvanced Drug Delivery Reviews, 2018
- Engineering nanoparticle strategies for effective cancer immunotherapyBiomaterials, 2018
- Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccineBiomaterials, 2017
- Differential Intrasplenic Migration of Dendritic Cell Subsets Tailors Adaptive ImmunityCell Reports, 2016
- Biomaterials for Nanoparticle Vaccine Delivery SystemsPharmaceutical Research, 2014